↓ Skip to main content

Continuous treatment with antidementia drugs in Germany 2003–2013: a retrospective database analysis

Overview of attention for article published in International Psychogeriatrics, April 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

news
1 news outlet
twitter
1 X user
facebook
1 Facebook page

Citations

dimensions_citation
28 Dimensions

Readers on

mendeley
52 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Continuous treatment with antidementia drugs in Germany 2003–2013: a retrospective database analysis
Published in
International Psychogeriatrics, April 2015
DOI 10.1017/s1041610215000654
Pubmed ID
Authors

Jens Bohlken, Simon Weber, Michael A. Rapp, Karel Kostev

Abstract

Continuous treatment is an important indicator of medication adherence in dementia. However, long-term studies in larger clinical settings are lacking, and little is known about moderating effects of patient and service characteristics. Data from 12,910 outpatients with dementia (mean age 79.2 years; SD = 7.6 years) treated between January 2003 and December 2013 in Germany were included. Continuous treatment was analysed using Kaplan-Meier curves and log-rank tests. In addition, multivariate Cox regression models were fitted with continuous treatment as dependent variable and the predictors antidementia agent, age, gender, medical comorbidities, physician specialty, and health insurance status. After one year of follow-up, nearly 60% of patients continued drug treatment. Donezepil (HR: 0.88; 95% CI: 0.82-0.95) and memantine (HR: 0.85; 0.79-0.91) patients were less likely to be discontinued treatment as compared to rivastigmine users. Patients were less likely to be discontinued if they were treated by specialist physicians as compared to general practitioners (HR: 0.44; 0.41-0.48). Younger male patients and patients who had private health insurance had a lower discontinuation risk. Regarding comorbidity, patients were more likely to be continuously treated with the index substance if a diagnosis of heart failure or hypertension had been diagnosed at baseline. Our results imply that besides type of antidementia agent, involvement of a specialist in the complex process of prescribing antidementia drugs can provide meaningful benefits to patients, in terms of more disease-specific and continuous treatment.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Unknown 51 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 10 19%
Researcher 9 17%
Student > Ph. D. Student 9 17%
Student > Bachelor 8 15%
Student > Postgraduate 3 6%
Other 4 8%
Unknown 9 17%
Readers by discipline Count As %
Medicine and Dentistry 18 35%
Nursing and Health Professions 7 13%
Pharmacology, Toxicology and Pharmaceutical Science 6 12%
Social Sciences 3 6%
Business, Management and Accounting 1 2%
Other 4 8%
Unknown 13 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 July 2015.
All research outputs
#3,064,118
of 22,800,560 outputs
Outputs from International Psychogeriatrics
#285
of 1,945 outputs
Outputs of similar age
#41,531
of 265,536 outputs
Outputs of similar age from International Psychogeriatrics
#5
of 45 outputs
Altmetric has tracked 22,800,560 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,945 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.5. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,536 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.